Lupin’s US Advair Generic Plans Turn Awry As Celon Pact Nears End

UK Fostair Approval Could Dampen Impact

Lupin’s plans for a US generic to GSK’s Advair Diskus have turned awry as its contract with Celon Pharma is close to being terminated. The company has focused on other respiratory drugs like generic ProAir and Fostair even as the revenue potential for Advair has been shrinking post Mylan’s launch.

Single Person Shaking Hands Partnership Break Up Concept
Lupin-Celon Partnership Close To End • Source: Alamy

Lupin Limited’s plans for a US generic to GlaxoSmithKline plc’s blockbuster Advair Diskus (fluticasone propionate/salmeterol) are coming undone as a 2015 partnership with the Polish company Celon Pharma SA to jointly develop the dry powder inhaler (DPI) product is close to being terminated.

An industry source told Scrip the deal was nearing its end, while a Lupin spokesperson declined to comment when contacted....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip